Immuno oncology News and Research

RSS

Novel computational platform can expand the pool of cancer immunotherapy targets

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

17 May 2023

Many melanoma patients could avoid the risk for toxicity from combination therapies, study suggests

Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.

17 Apr 2023

Using tiny bubbles to improve gene therapy

Beyond vaccines, mRNA offers immense potential to fight disease, but targeting the genetic material to specific diseased cells is challenging-; requiring a new method.

11 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

3D Printing the Way to New Cancer Treatments

In this interview, we speak to Ishani Malhotra, CEO of Carcinotech, about their 3D-printed tumor replicas that are being used to better understand personalized cancer treatments.

3 Apr 2023

Study shows how neutrophils play a key role in cancer immunotherapy success

Cancer immunotherapies that recruit a patient's own immune system to destroy tumors have transformed the treatment of many types of cancer. Yet these therapies do not elicit universally good treatment responses.

30 Mar 2023

Targeting the STING pathway with a combination strategy promotes antitumor activity

Immunotherapies have greatly improved the outcomes of many patients with melanoma. But there is still a need for new approaches for the subset of patients who do not respond well to this type of therapy.

27 Mar 2023

Immunochemistry multiplex for solid tumor analytical validation

In this interview, NewsMedical exchanges with Cerba on how to use T-regulatory immunochemsitry multiplex for solid tumor analytical validation.

From Cerba Research 16 Mar 2023

Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

15 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

A combination of chemotherapy and drugs that stimulate the immune system to combat cancer is increasingly used to control progression of the disease in patients.

30 Jan 2023

New tool can accurately discover, quantify RNA molecules from error-prone long-read RNA sequencing data

On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.

20 Jan 2023

Insilico Medicine launches a 6th generation Intelligent Robotics Drug Discovery Laboratory

Insilico Medicine, a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

5 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

5 Jan 2023

Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy

Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform.

27 Dec 2022

Innovative precision oncology enabled by micro-organospheres derived from patients

The development of an automatic microfluidics droplet platform to rapidly generate patient-derived models of cancer.

6 Dec 2022

Government introduces a Vaccine Taskforce style approach to tackle public health challenges in the UK

NHS patients are set to benefit from cutting-edge new treatments and technologies as the government introduces a Vaccine Taskforce style approach to tackling some of the biggest public health challenges facing the UK.

27 Nov 2022

IVI and Lemonex sign MOU to join forces on vaccine development

The International Vaccine Institute announced on November 10 it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

10 Nov 2022

EVIDENT and Ultivue collaborate to advance multiplex slide imaging and spatial analysis in translational research

Evident Corporation, a premier manufacturer of life science imaging systems, and Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas.

From Evident Corporation - Life Sciences 10 Nov 2022

Celebrating the Alderley Park Grand Opening

HQ Plasmid Center of Excellence based at UK life science hotspot now open for business.

From Charles River Laboratories, Inc. 24 Oct 2022